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Background: Giant cell arteritis (GCA) is the most common primary systemic vasculitis
predominantly affecting large and medium sized vessels. In rare cases, the vasculitis can
affect the vessels of the brain.
Results: We describe four cases of GCA with involvement of the cerebral vessels
causing stroke. These cases were unresponsive to aggressive immunosuppression
and we opted to treat with endovascular balloon dilatation of the stenotic areas. The
procedure was safe. The four patients were treated in nine sessions and a total of
16 vessels were treated. We observed two dissections with no clinical influence on
the patients.
Discussion: In patients with stroke due to progressive GCA that is non-responsive to
immunosuppression, endovascular therapy is feasible.
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BACKGROUND
Giant cell arteritis (GCA) is the most common primary systemic vasculitis. It predominantly
affects large and mediums sized arteries, typically the aortic arch and its branches, and branches
of the external carotid artery. Women are affected 2–3 times more often than men. The classical
clinical presentation includes headache, scalp tenderness, jaw claudication, visual disturbances,
fever, and weight loss. Laboratory results show increased inflammatory markers. Biopsy of the
superficial temporal artery can show inflammation of the vessel wall (1). Involvement of the
intracerebral arteries and stroke have been described but are very rare. Treatment of GCA is
medical. Endovascular treatment has only been attempted very rarely (2).
PATIENTS AND METHODS
We reviewed our cases of GCA with stroke in the period of 2015–2018. The diagnosis of GCA
was clinical and followed the definition from American College of Rheumatology (3) demanding
three of five criteria: (1) Age >50 years. (2) New headache. (3) Temporal artery tenderness. (4)
Erythrocyte sedimentation rate >40 mm/h. (5) Positive biopsy of the superficial temporal artery.
We identified seven patients. Our approach to treatment was first to give high dose
glucocorticoid and 2/7 had remission of symptoms on prednisolone alone. In a third case, we added
pulses of i.v. cyclophosphamide (CPM) which stopped progression.
In the remaining four cases, where the disease was progressing with new transient
ischemic attacks (TIA) or strokes, we chose to proceed with balloon angioplasty and CPM to
suppress inflammation.
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Balloon angioplasty was performed in three patients (case
1, 2, and 3, see below) with a non-compliant balloon catheter
(Gateway, Stryker, Kalamazoo, MI). The stenoses were dilated
to a maximum of 80% of the estimated normal vessel diameter,
with at least two repetitive dilatations with successively increasing
atmospheric pressures (see Figures 1, 2). The immediate
angiographic results were excellent in all cases with an increase
of the vessel diameter to 70–80% at the level of the stenosis.
FIGURE 1 | Digital subtraction angiography of case 1, lateral view of the left
internal carotid artery. Two stenosis are seen.
FIGURE 2 | The same artery after balloon dilatation.
In two of the cases (case 3 in the first treatment round and
in case 4) it was not possible to cross the stenotic lesions by
the balloon catheter. Angioplasty was instead performed with an
adjustable remodeling mesh device, the Comaneci stent (Rapid
Medical, Yokneam, Israel), in three stenoses at the level of the
siphon and one V4 stenosis. We saw good results in the three
siphon stenoses (a triple increase of the diameter in two cases and
a double increase in one) and a modest effect on the V4-stenosis
with an increase of the diameter of 20%.
Angioplasty was repeated twice in two patients and three
times in one patient, with intervals of 2 weeks and 3 months.
Examples of angioplasty from all the cases can be seen in
Supplementary Materials.
CASES
Case 1
A 65-year old woman with no vascular risk factors was admitted
with sudden aphasia and decreased sensation of the right arm.
The patient complained of two episodes during the previous week
with weakness of the right arm and 2 days later weakness of the
left arm. Both episodes lasted 20min. Also, she had experienced
headache, jaw claudication and fatigue for the last 2 months.
Diffusion-weighted MRI showed bilateral ischemic lesions
and MR angiography showed stenosis of both internal carotid
arteries (ICAs) at the level of the carotid siphon. Cerebrospinal
fluid (CSF) was normal. Oral high dose prednisone (1 mg/kg)
was started.
The headache and jaw claudication resolved on this
treatment, but the patient had progressive episodes of aphasia.
Glucocorticoid treatment was increased to methylprednisone 1 g
i.v. daily for 3 days followed by oral prednisone 100mg daily
with a taper. Tocilizumab was added, but the patient continued
to suffer TIAs and small strokes resulting in worsening aphasia.
Ten days after admission, balloon dilatation was performed on
the left ICA. Figures 1, 2 show a digital subtraction angiography
of the stenosis before and after dilatation. She was followed with
transcranial color-coded sonography (TCCS). Repeat balloon
angioplasty of the left ICA was performed 1 month later when
TCCS showed worsening of the stenosis.
CPM was started (first dose i.v. 15 mg/kg and then 2 mg/kg
orally daily). This was given for a total of 6 months and the
patient was transitioned to methotrexate. The patient had no
further strokes. The 90-day outcome for all the patients is found
in Table 1.
Case 2
Sixty-four-year old woman with a past medical history of
hypertension and diabetes. She presented with severe headache
3 months before she was diagnosed with GCA. Two days
after starting high dose oral glucocorticoids, she was admitted
with wordfinding difficulties. Angiography showed bilateral
stenosis of the intracerebral ICAs. Glucocorticoid treatment was
increased tomethylprednisone 1 g i.v. daily for 3 days followed by
oral prednisone 100mg daily with a taper. She was treated with
balloon angioplasty of the left ICA and had a small dissection. She
was started on i.v. CPM (15 mg/kg, every 3 weeks.)
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TABLE 1 | Summary of the key findings and treatment details in the patients.
Patient # Initial ESR Biopsy of STA PET scan Number of
treatments, number
of vessels treated
and complication
Medical treatment
besides prednisone
Time between
first stroke and
treatment
90 day mRS
1 46 Positive Positive. FDG
uptake in maxillary
and vertebral artery
2 treatments, 1 vessel
(left ICAx2). No
complications
I.v. CPM 15 mg/kg x1,
then oral CPM 2 mg/kg
daily for 6 months
10 days 2
2 57 Positive None 3 treatments, left
ICAx3, right ICAx2. 1
dissection
I.v. CPM 15 mg/kg x6 2 days 3
3 22 Positive Positive. FDG
uptake in maxillary,
vertebral and STA
2 treatments. Left
ICAx2, right ICAx1, left
vertebral x1. No
complications.
I.v. CPM 10 mg/kg x6 2 weeks
(progressive
apraxia and
apathy)
1
4 54 Non-specific None 2 treatments. Left
ICAx2, right ICAx2, left
vertebral x1, 1
dissection
I.v. CPM 15 mg/kg x6 Acute treatment
(TIA 14 days
prior.)
4
CPM, Cyclophosphamide; ESR, Erythrocyte Sedimentation Rate; FDG, Fluor-deoxy-glucose; ICA, Internal carotid artery; mRS, modified rankin scale; PET, Positron emission tomography;
STA, Superficial temporal artery; TIA, Transient Ischemic Attack.
She was admitted again 2 weeks later with apathy and
gait disturbances. A further MRI scan showed progressive
bilateral anterior infarcts and she was again treated with balloon
angioplasty of both intracerebral ICAs. She was readmitted 1
month later after a fall. No new lesions were seen on MRI, but
both ICAs were dilated again as a precaution. She had no new
documented strokes after the second treatment.
Her course was complicated with pneumocystis pneumonia
successfully treated with Sulfamethoxazole/Trimethoprim. After
6 cycles of i.v. CPM, she was transitioned to methotrexate.
Case 3
Seventy-two-year old male with a history of hypertension,
diabetes, smoking, and colon cancer. He was admitted with
sudden vision loss on the right eye, increasing tiredness,
headache, weight loss of 7 kg, and isolation from social activities.
A diagnosis of GCA was made and the patient was started
on methylprednisone 1 g i.v. daily for 3 days followed by oral
prednisone 100mg daily with a taper. When he reached 20mg
daily, he was readmitted due to forgetfulness, speech difficulties,
and apraxia. CSF was normal. An MRI revealed ischemic lesions
in the watershed areas in the left hemisphere (Figure 3). He was
re-started on high dose glucocorticoid (1 g methylprednisone
i.v. daily for 3 days followed by oral prednisone 100mg daily
with a taper) and was treated with balloon angioplasty of a
stenosis in the left carotid siphon. This treatment was 110 days
after the initial presentation. Figure 4 illustrates the characteristic
stenotic lesion.
Two weeks after the initial angioplasty he was readmitted,
again with a change in personality and apathy. He was again
treated by angioplasty of both intracranial ICAs. After the first
endovascular treatment, he was started on CPM 10 mg/kg every
3 weeks for a total of 6 treatments and then transitioned to
methotrexate. He was followed in the outpatient clinic with no
new complains.
FIGURE 3 | Ischemic lesion in the left hemisphere distributed in the watershed
area in case number 3. This indicates an embolic source or compromised flow
in the left internal carotid artery.
Case 4
Seventy-one-year old woman with only mild hypertension. She
was seen with a TIA (left sided weakness), but then admitted 2
weeks later with severe left sided weakness. She was taken for
thrombectomy and the angiography revealed multiple stenoses.
Balloon dilatation was performed on the right intracranial
ICA. Retrospectively, she complained about headache and jaw
claudication 1 month prior to the TIA. CSF was normal. She was
started on 1 g of methylprednisone i.v. daily for 3 days followed
by oral prednisone 100mg daily with a taper. A few days after
the initial treatment, paresis on the left side became worse and
a new MRI revealed an infarct in the pons. She was taken for
angiography again 7 days after the first treatment, and stenosis
Frontiers in Neurology | www.frontiersin.org 3 April 2020 | Volume 11 | Article 287
Simonsen et al. Balloon Angioplasty of Vasculitis
FIGURE 4 | This is the stenotic lesion in the internal carotid artery in case
number 3.
on both the carotids and the left vertebral arteries were treated.
The dilation of the vertebral was complicated with a dissection.
She was started on i.v. CPM 15 mg/kg every 3 weeks for 6
treatments and transitioned to methotrexate. She had no new
strokes after this.
DISCUSSION
In this case series, we present patients with strokes on the basis
of GCA. Some of the cases progressed regardless of high dose
glucocorticoids and intervention with balloon angioplasty of
cerebral vessels was performed as a rescue therapy.
The intervention was done with minimal complications. A
total of 16 vessel-treatments were performed and we only saw
two dissections evident on angiography, which did not cause any
symptoms. Our impression was that rescue balloon angioplasty
is safe and maybe beneficial together with immunosuppression
after steroid failure.
Stroke has been described before as a complication of GCA.
In a new French study, the patients with GCA and stroke were
more often older and more frequently men compared to patients
with GCA and no strokes (4). This is in contrast to the sex
distribution in GCA, where women are affected more often. Also,
the frequency of ocular involvement was higher in the patients
who subsequently had stroke. Another large retrospective study
also found a high rate of ocular ischemia and a higher age
among patients with stroke due to GCA, but a more even sex
distribution (5).
Intracerebral stenosis in GCA can respond to high dose
glucocorticoids (6). But it has been reported previously that
the progression of strokes in some cases do not respond to
glucocorticoid treatment (7). Progression of strokes has also
been described after initiation of glucocorticoid treatment and
a clinical response to the systemic symptoms (8, 9). After the
success of endovascular therapy in acute ischemic stroke (10) and
relatively few side effects, it was a logical step to try this option in
patients with progressive symptoms and large vessel stenosis on
inflammatory background.
We have only found balloon dilatation and stenting described
before in three single cases (11–13). The use of stent retrievers
in the treatment of cerebral vasospasm in patients with
subarachnoid hemorrhage has been described recently (14) and
the technique was adopted in cases due to failure of performing
balloon angioplasty.
As aggressive medical treatment beyond high dose
glucocorticoid, we chose CPM. This drug is generally
chosen to control severe cases of cerebral vasculitis. The
patient in case 1 was treated with the interleukin-6 receptor
inhibitor tocilizumab. This drug has shown to be effective
in obtaining remission in patients with GCA together
with lower cumulated doses of glucocorticoid (15). In
our case, the patient’s strokes continued after initiation
of tocilizumab.
The limitations to our study are that the patients were not
prospectively collected and treated on a case by case nature.
Our aim with this paper is to report that progression of
neurological symptoms in a patient with GCA should lead to
aggressive treatment with high dose glucocorticoid and CPM.
Endovascular therapy with angioplasty for severe symptomatic
stenosis in this setting can be considered and appears to be
reasonable safe.
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PRESENTATION 1| Here are examples of digital subtraction
angiography of the 4 treated patients before and after
balloon angioplasty.
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